Enjoy complimentary customisation on priority with our Enterprise License!
The Premature Ejaculation (PE) Treatment Market size is estimated to grow by USD 1,459.85 million at a CAGR of 8.78% between 2023 and 2028.
Premature ejaculation treatment market Share
For More Highlights About this Report, Download Free Sample in a Minute
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The high efficacy of off-label premature ejaculation drugs is a major driver boosting the market growth. The global market for premature ejaculation treatment faces limitations in approved products, being predominantly driven by off-label drugs, generic versions, and over-the-counter formulations. The market's growth is propelled by the increasing demand for off-label drugs, notably SSRIs like paroxetine, fluoxetine, and sertraline, which were originally designed for mental health disorders but have shown effectiveness in delaying ejaculation. SSRIs, particularly paroxetine, exhibit a significant anti-ejaculatory effect within five to ten days.
PDE5 inhibitors, recognized as the primary treatment for erectile dysfunction, also demonstrate promise in treating premature ejaculation. Combining PDE5 inhibitors with SSRIs proves more effective than using SSRIs alone, as the improved erection inhibits ejaculation. Both drug classes are considered safe and effective for managing premature ejaculation, leading to widespread off-label use. The high efficacy of these drugs contributes to increased demand, propelling the growth of the global premature ejaculation treatment market during the forecast period.
The advent of nanotechnology in premature ejaculation treatment drugs is a key trend shaping the market. Introduced in the 1980s, nanotechnology has revolutionized drug delivery system development for various diseases. Over the past decades, numerous nanotechnology-associated technologies have been clinically utilized, benefiting countless patients and promising a bright future for nanotechnology in medicine.
PDE-5 inhibitors like tadalafil, sildenafil, and vardenafil find off-label use in premature ejaculation treatment, but their oral administration poses challenges due to poor solubility and systemic side effects. Similarly, dapoxetine, an SSRI, faces low bioavailability orally. Nanotechnology offers new avenues for drug delivery, as demonstrated in a study by Han et al. Nanoparticles present a potential topical delivery route for erectogenic agents, improving safety profiles and minimizing side effects compared to oral administration or injections. In summary, nanotechnology opens new possibilities in drug delivery systems, contributing to market growth during the forecast period.
The availability of alternative treatment options for premature ejaculation is a key challenge hindering the market growth. While the market for premature ejaculation has limited approved products, the rising global cases have prompted alternative treatments' adoption, such as counseling, homeopathy, psychotherapy, yoga, and herbal therapy. Natural options like ginseng tea, raw almond milk, and Ayurvedic remedies are also considered.
Psychotherapy and behavioral therapies are common approaches, with psychotherapy being the first line for subjective premature ejaculation or cases with underlying psychological issues. However, it is time-consuming, costly, and less effective than pharmacotherapy. Psychosexual counseling addresses distress, while methods like meditation, hypnotherapy, and neuro-biofeedback enhance ejaculatory control. Behavioral therapies include techniques like precoital masturbation, stop-start and squeeze methods, condom use, and pelvic floor exercises. Breathing exercises, Kegel exercises, and Ayurvedic massage are recommended with minimal side effects compared to mainstream drugs. The growing popularity of these alternatives poses a threat to pharmaceutical therapies' growth in the market during the forecast period.
The market share growth by the oral segment will be significant during the forecast period. The significant market share of the oral route segment can be attributed to the popularity and high preference for oral medication as the first line of treatment for premature ejaculation, owing to its ease of use and wide availability. These drugs are available in different forms, such as tablets, capsules, and liquids.
Get a glance at the market contribution of various segments Download the PDF Sample
The oral segment was the largest and was valued at USD 1,358.46 million in 2018. SSRIs were then used due to their sustained efficacy on ejaculatory latency and tolerable side effect profile. The mechanism for delayed ejaculation with SSRIs probably relates to the inhibition of multiple descending pathways associated with the ejaculatory reflex. This is supported by studies that show significant variations in cortical serotonergic function between patients with premature ejaculation in males. However, the non-availability of approved oral drugs to treat premature ejaculation in the US is attracting many large pharmaceutical companies to capitalize on the premature ejaculation (PE) treatment market by investing in R&D programs and developing new solutions. Such factors are expected to drive the growth of the oral segment in the market in focus during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
North America dominates the premature ejaculation treatment market, primarily due to a significant rise in the number of premature ejaculation cases, owing to psychological strain and stress from an ever-changing lifestyle. Premature ejaculation is the most common sexual disorder in men younger than 40 years, with some degree at one time or another, which presents a significant market opportunity in the US alone. Several top vendors are headquartered in the region. They are either already offering premature ejaculation drugs or will be launching their products soon after approval from the US FDA.
In addition, the presence of off-label premature ejaculation solution providers such as Eli Lilly and Co. and Pfizer Inc. in the region has offered an alternate solution for the condition at a cheaper cost. An increase in the number of premature ejaculation cases will be addressed through a broad range of products in the pipeline. Increased R&D spending will further boost the growth of the regional premature ejaculation treatment market. Therefore, such factors are expected to drive the growth of the regional market during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
A. Menarini Industrie Farmaceutiche Riunite Srl - The company offers premature ejaculation treatments such as Priligy and Spedra.
The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Premature Ejaculation Treatment Market Scope |
|
Report Coverage |
Details |
Page number |
167 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 8.78% |
Market growth 2024-2028 |
USD 1,459.85 million |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
7.34 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 38% |
Key countries |
US, Italy, UK, China, and India |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
A. Menarini Industrie Farmaceutiche Riunite Srl, Absorption Pharmaceuticals LLC, Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Aytu BioPharma Inc., Bayer AG, Eli Lilly and Co., Futura Medical plc, GlaxoSmithKline Plc, Johnson and Johnson, LloydsPharmacy, Morari Inc., NeuroHealing Pharmaceuticals Inc., Niksan Pharmaceutical, Pfizer Inc., Plethora Solutions Ltd., Prinston Pharmaceutical Inc., Ralington Pharma LLP, Sunrise Remedies Pvt. Ltd., Tabuk Pharmaceuticals, Veru Inc., and VIVUS LLC |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.